연구동향 분석
박사

Preparation and characterization of self-assembled nanoparticles based on low-molecular-weight heparin and stearylamine conjugates for controlled delivery of docetaxel : 도세탁셀의 약물전달을 위한 저분자량 헤파린과 스테아릴아민 중합체를 이용한 자가조립나노입자의 제조 및 평가

김동환 2015년

논문상세정보
인용/피인용
' Preparation and characterization of self-assembled nanoparticles based on low-molecular-weight heparin and stearylamine conjugates for controlled delivery of docetaxel : 도세탁셀의 약물전달을 위한 저분자량 헤파린과 스테아릴아민 중합체를 이용한 자가조립나노입자의 제조 및 평가' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • docetaxel
  • drug delivery
  • low-molecular-weight heparin
  • self-assembled nanoparticle
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
109 0

0.0%

' Preparation and characterization of self-assembled nanoparticles based on low-molecular-weight heparin and stearylamine conjugates for controlled delivery of docetaxel : 도세탁셀의 약물전달을 위한 저분자량 헤파린과 스테아릴아민 중합체를 이용한 자가조립나노입자의 제조 및 평가' 의 참고문헌

  • Z. Liu, Y. Jiao, Y. Wang, C. Zhou. and Z. Zhang, Polysaccharides-based nanoparticles asdrug delivery systems, Adv. Drug Deliv. Rev. 60 (2008) 1650-1662.
  • Z. Liu, Y. Jiao, Y. Wang, C. Zhou, Z. Zhang, Polysaccharides-based nanoparticles as drugdelivery systems, Advanced Drug Delivery Reviews, 60 (2008) 1650-1662.
  • Y.-M. Yin, F.-D. Cui, C.-F. Mu, M.-K. Choi, J.S. Kim, S.-J. Chung, C.-K. Shim. and D.-D. Kim, Docetaxel microemulsion for enhanced oral bioavailability: Preparation and in vitroand in vivo evaluation, J. Control. Release. 140 (2009) 86-94.
  • Y. Wu, J.A. MacKay, J. R. McDaniel, A. Chilkoti. and R.L. Clark, Fabrication of elastinlikepolypeptide nanoparticles for drug delivery by electrospraying, Biomacromolecules. 10(2008) 19-24.
  • Y. Wu, J.A. MacKay, J. R. McDaniel, A. Chilkoti, R.L. Clark, Fabrication of elastin-likepolypeptide nanoparticles for drug delivery by electrospraying, Biomacromolecules, 10 (2008)19-24.
  • Y. Wang, D. Xin, K. Liu, M. Zhu, J. Xiang, Heparin? Paclitaxel conjugates as drugdelivery system: synthesis, self-assembly property, drug release, and antitumor activity,Bioconjugate Chemistry, 20 (2009) 2214-2221.
  • Y. Min, M. Akbulut, K. Kristiansen, Y. Golan. and J. Israelachvili, The role ofinterparticle and external forces in nanoparticle assembly, Nature Materials. 7 (2008) 527-538.
  • X.-G. Chen, C.M. Lee, H.-J. Park, O/W emulsification for the self-aggregation andnanoparticle formation of linoleic acid modified chitosan in the aqueous system, Journal ofAgricultural and Food Chemistry, 51 (2003) 3135-3139.
  • X. Shao, Q. Liu, C. Zhang, X. Zheng, J. Chen, Y. Zha, Y. Qian, X. Zhang, Q. Zhang. andX. Jiang, Concanavalin A-conjugated poly (ethylene glycol)-poly (lactic acid) nanoparticlesfor intranasal drug delivery to the cervical lymph nodes, J. Microencapsul. (2013) 1-7.
  • X. Shao, Q. Liu, C. Zhang, X. Zheng, J. Chen, Y. Zha, Y. Qian, X. Zhang, Q. Zhang, X.Jiang, Concanavalin A-conjugated poly (ethylene glycol)-poly (lactic acid) nanoparticles forintranasal drug delivery to the cervical lymph nodes, Journal of Microencapsulation, (2013)1-7.
  • V. Labhasetwar, C. Song, W. Humphrey, R. Shebuski. and R.J. Levy, Arterial uptake ofbiodegradable nanoparticles: effect of surface modifications, J. Pharm. Sci. 87 (1998) 1229-1234.
  • V. Labhasetwar, C. Song, W. Humphrey, R. Shebuski, R.J. Levy, Arterial uptake ofbiodegradable nanoparticles: effect of surface modifications, Journal of PharmaceuticalSciences, 87 (1998) 1229-1234.12
  • U. Termsarasab, H.-J. Cho, D.H. Kim, S. Chong, S.-J. Chung, C.-K. Shim, H.T. Moon.and D.-D. Kim, Chitosan oligosaccharide?arachidic acid-based nanoparticles for anti-cancerdrug delivery, Int. J. Pharm. 441 (2013) 373-380.
  • U. Termsarasab, H.-J. Cho, D.H. Kim, S. Chong, S.-J. Chung, C.-K. Shim, H.T. Moon,D.-D. Kim, Chitosan oligosaccharide?arachidic acid-based nanoparticles for anti-cancer drugdelivery, International Journal of Pharmaceutics, 441 (2013) 373-380.
  • T.M.H. Niers, C.P.W. Klerk, M. DiNisio, C.J.F. Van Noorden, H.R. Buller, P.H. Reitsma.and D.J. Richel, Mechanisms of heparin induced anti-cancer activity in experimental cancermodels, Crit. Rev. Oncol./Hematol. 61 (2007) 195-207.
  • T.M.H. Niers, C.P.W. Klerk, M. DiNisio, C.J.F. Van Noorden, H.R. Buller, P.H. Reitsma,D.J. Richel, Mechanisms of heparin induced anti-cancer activity in experimental cancermodels, Critical Reviews in Oncology/Hematology, 61 (2007) 195-207.
  • T. Verrecchia, G. Spenlehauer, D. Bazile, A. Murry-Brelier, Y. Archimbaud. and M.Veillard, Non-stealth (poly (lactic acid/albumin)) and stealth (poly (lactic acid-polyethyleneglycol)) nanoparticles as injectable drug carriers, J. Control. Release. 36 (1995) 49-61.
  • T. Verrecchia, G. Spenlehauer, D. Bazile, A. Murry-Brelier, Y. Archimbaud, M. Veillard,Non-stealth (poly (lactic acid/albumin)) and stealth (poly (lactic acid-polyethylene glycol))nanoparticles as injectable drug carriers, Journal of Controlled Release, 36 (1995) 49-61.
  • T. Jung, W. Kamm, A. Breitenbach, E. Kaiserling, J. Xiao, T. Kissel, Biodegradablenanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosaluptake?, European Journal of Pharmaceutics and Biopharmaceutics, 50 (2000) 147-160.
  • S.M. Smorenburg, C.J. Van Noorden, The complex effects of heparins on cancerprogression and metastasis in experimental studies, Pharmacological Reviews, 53 (2001) 93-106.
  • S.M. Smorenburg and C.J. Van Noorden, The complex effects of heparins on cancerprogression and metastasis in experimental studies, Pharmacol. Rev. 53 (2001) 93-106.
  • S.J. Clarke and L.P. Rivory, Clinical pharmacokinetics of docetaxel, Clinicalpharmacokinetics. 36 (1999) 99-114.
  • S.D. Conner and S.L. Schmid, Regulated portals of entry into the cell, Nature. 422 (2003)37-44.
  • S.D. Baker, A. Sparreboom. and J. Verweij, Clinical pharmacokinetics of docetaxel,Clinical pharmacokinetics. 45 (2006) 235-252.
  • S. Sharma, H.A. Benson, T.K. Mukkur, P. Rigby. and Y. Chen, Preliminary studies on thedevelopment of IgA-loaded chitosan-dextran sulphate nanoparticles as a potential nasaldelivery system for protein antigens, J. Microencapsul. 30 (2013) 283-294.
  • S. Sharma, H.A. Benson, T.K. Mukkur, P. Rigby, Y. Chen, Preliminary studies on thedevelopment of IgA-loaded chitosan-dextran sulphate nanoparticles as a potential nasaldelivery system for protein antigens, Journal of Microencapsulation, 30 (2013) 283-294.
  • S. Li, B. Byrne, J. Welsh. and A.F. Palmer, Self?Assembled Poly (butadiene)?b?poly(ethylene oxide) Polymersomes as Paclitaxel Carriers, Biotechnology progress. 23 (2007)278-285.
  • S. Kaida, H. Cabral, M. Kumagai, A. Kishimura, Y. Terada, M. Sekino, I. Aoki, N.Nishiyama, T. Tani, K. Kataoka, Visible drug delivery by supramolecular nanocarriersdirecting to single-platformed diagnosis and therapy of pancreatic tumor model, CancerResearch, 70 (2010) 7031-7041.
  • S. Aishwarya, S. Mahalakshmi. and P.K. Sehgal, Collagen-coated polycaprolactone46microparticles as a controlled drug delivery system, J. Microencapsul. 25 (2008) 298-306.
  • S. Aishwarya, S. Mahalakshmi, P.K. Sehgal, Collagen-coated polycaprolactonemicroparticles as a controlled drug delivery system, Journal of Microencapsulation, 25 (2008)298-306.
  • R.D. Rosenberg, Heparin, antithrombin, and abnormal clotting, Annual Review ofMedicine, 29 (1978) 367-378.
  • R. Castelli, F. Porro. and P. Tarsia, The heparins and cancer: review of clinical trials andbiological properties, Vascular Medicine. 9 (2004) 205-213.48
  • R. Castelli, F. Porro, P. Tarsia, The heparins and cancer: review of clinical trials andbiological properties, Vascular Medicine, 9 (2004) 205-213.
  • P.E. Thorpe, E.J. Derbyshire, S.P. Andrade, N. Press, P.P. Knowles, S. King, G.J. Watson,Y.-C. Yang. and M. Rao-Bette, Heparin-steroid conjugates: new angiogenesis inhibitors withantitumor activity in mice, Cancer Res. 53 (1993) 3000-3007.
  • P. Sun, Y. Zhang, L. Shi. and Z. Gan, Thermosensitive Nanoparticles Self?Assembledfrom PCL?b?PEO?b?PNIPAAm Triblock Copolymers and their Potential for Controlled DrugRelease, Macromolecular bioscience. 10 (2010) 621-631.
  • P. Lim Soo and A. Eisenberg, Preparation of block copolymer vesicles in solution,Journal of Polymer Science Part B: Polymer Physics. 42 (2004) 923-938.
  • N. Rizkalla, C. Range, F.-X. Lacasse. and P. Hildgen, Effect of various formulationparameters on the properties of polymeric nanoparticles prepared by multiple emulsionmethod, J. Microencapsul. 23 (2006) 39-57.
  • N. Rizkalla, C. Range, F.-X. Lacasse, P. Hildgen, Effect of various formulationparameters on the properties of polymeric nanoparticles prepared by multiple emulsionmethod, Journal of Microencapsulation, 23 (2006) 39-57.
  • M.L. Immordino, P. Brusa, S. Arpicco, B. Stella, F. Dosio. and L. Cattel, Preparation,characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel, J.Control. Release. 91 (2003) 417-429.
  • M.A. Jordan and K. Kamath, How do microtubule-targeted drugs work? An overview,Current Cancer Drug Targets. 7 (2007) 730-742.
  • M. Marchetti, A. Vignoli, L. Russo, D. Balducci, M. Pagnoncelli, T. Barbui. and A.Falanga, Endothelial capillary tube formation and cell proliferation induced by tumor cellsare affected by low molecular weight heparins and unfractionated heparin, Thromb. Res. 121(2008) 637-645.
  • M. Marchetti, A. Vignoli, L. Russo, D. Balducci, M. Pagnoncelli, T. Barbui, A. Falanga,Endothelial capillary tube formation and cell proliferation induced by tumor cells are affectedby low molecular weight heparins and unfractionated heparin, Thrombosis Research, 121(2008) 637-645.
  • M. Jahanshahi, Z. Babaei, Protein nanoparticle: A unique system as drug deliveryvehicles, African Journal of Biotechnology, 7 (2008) 4926-4934.
  • M. Jahanshahi and Z. Babaei, Protein nanoparticle: A unique system as drug deliveryvehicles, Afr. J. Biotechnol. 7 (2008) 4926-4934.
  • L. Hou, J. Yao, J. Zhou, Q. Zhang, Pharmacokinetics of a paclitaxel-loaded lowmolecular weight heparin-all-trans-retinoid acid conjugate ternary nanoparticulate drugdelivery system, Biomaterials, 33 (2012) 5431-5440.
  • K.Y. Choi, H. Chung, K.H. Min, H.Y. Yoon, K. Kim, J.H. Park, I.C. Kwon, S.Y. Jeong,Self-assembled hyaluronic acid nanoparticles for active tumor targeting, Biomaterials, 31(2010) 106-114.
  • K.S. Jee, H.D. Park, K.D. Park, Y.H. Kim, J.-W. Shin, Heparin conjugated polylactide as15a blood compatible material, Biomacromolecules, 5 (2004) 1877-1881.
  • K.H. Bae, H. Mok. and T.G. Park, Synthesis, characterization, and intracellular deliveryof reducible heparin nanogels for apoptotic cell death, Biomaterials. 29 (2008) 3376-3383.
  • K.H. Bae, H. Mok, T.G. Park, Synthesis, characterization, and intracellular delivery ofreducible heparin nanogels for apoptotic cell death, Biomaterials, 29 (2008) 3376-3383.
  • K.A. Lyseng-Williamson and C. Fenton, Docetaxel, Drugs. 65 (2005) 2513-2531.
  • K. Park, K. Kim, I.C. Kwon, S.K. Kim, S. Lee, D.Y. Lee, Y. Byun, Preparation andcharacterization of self-assembled nanoparticles of heparin-deoxycholic acid conjugates,Langmuir, 20 (2004) 11726-11731.
  • K. Park, G.Y. Lee, Y.-S. Kim, M. Yu, R.-W. Park, I.-S. Kim, S.Y. Kim. and Y. Byun,Heparin?deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumoractivity, J. Control. Release. 114 (2006) 300-306.
  • K. Park, G.Y. Lee, Y.-S. Kim, M. Yu, R.-W. Park, I.-S. Kim, S.Y. Kim, Y. Byun,Heparin?deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumoractivity, Journal of Controlled Release, 114 (2006) 300-306.
  • K. Park, G.Y. Lee, R.-W. Park, I.-S. Kim, S.Y. Kim. and Y. Byun, Combination Therapyof Heparin?Deoxycholic Acid Conjugate and Doxorubicin against Squamous Cell Carcinoma49and B16F10 Melanoma, Pharm. Res. 25 (2008) 268-276.
  • K. Park, G.Y. Lee, R.-W. Park, I.-S. Kim, S.Y. Kim, Y. Byun, Combination therapy ofheparin?deoxycholic acid conjugate and doxorubicin against squamous cell carcinoma andB16F10 melanoma, Pharmaceutical Research, 25 (2008) 268-276.
  • K. Kolishetti, S. Dhar, PM. Valencia, LQ. Lin, R. Karnik, SJ. Lippard, R. Langer, OC.Farokhzad, Engineering of self-assembled nanoparticle platform for precisely controlledcombination drug therapy, PNAS, 107 (2010) 17939-17944.
  • J.S. Lee, D.H. Go, J.W. Bae, S.J. Lee, K.D. Park, Heparin conjugated polymeric micellefor long-term delivery of basic fibroblast growth factor, Journal of Controlled Release, 117(2007) 204-209.
  • J.S. Lee, D.H. Go, J.W. Bae, I.K. Jung, J.W. Lee. and K.D. Park, Synthesis andcharacterization of heparin conjugated Tetronic?? ?PCL copolymer for protein drug delivery,Curr. Appl. Phys. 7 (2007) e49-e52.
  • J.S. Lee, D.H. Go, J.W. Bae, I.K. Jung, J.W. Lee, K.D. Park, Synthesis andcharacterization of heparin conjugated Tetronic?? ?PCL copolymer for protein drug delivery,Current Applied Physics, 7 (2007) e49-e52.
  • J.P. Kratohvil, W.P. Hsu, D.I. Kwok, How large are the micelles of di-??-hydroxy bilesalts at the critical micellization concentrations in aqueous electrolyte solutions? Results forsodium taurodeoxycholate and sodium deoxycholate, Langmuir, 2 (1986) 256-258.
  • J. You, F.-Q. Hu, Y.-Z. Du, H. Yuan. and B.-F. Ye, High cytotoxicity and resistant-cell50reversal of novel paclitaxel loaded micelles by enhancing the molecular-target delivery of thedrug, Nanotechnology. 18 (2007) 495101-495107.
  • J. Nishioka, S. Goodin, Low-molecular-weight heparin in cancer-associated thrombosis:treatment, secondary prevention, and survival, Journal of Oncology Pharmacy Practice, 13(2007) 85-97.
  • J. Nishioka and S. Goodin, Low-molecular-weight heparin in cancer-associatedthrombosis: treatment, secondary prevention, and survival, J. Oncology Pharm. Practice. 13(2007) 85-97.
  • J. Molpeceres, M. Guzman, M.R. Aberturas, M. Chacon. and L. Berges, Application ofcentral composite designs to the preparation of polycaprolactone nanoparticles by solventdisplacement, J. Pharm. Sci. 85 (1996) 206-213.
  • J. Molpeceres, M. Guzman, M.R. Aberturas, M. Chacon, L. Berges, Application of centralcomposite designs to the preparation of polycaprolactone nanoparticles by solventdisplacement, Journal of Pharmaceutical Sciences, 85 (1996) 206-213.
  • J. Kreuter, Nanoparticles and microparticles for drug and vaccine delivery, Journal ofAnatomy, 189 (1996) 503-505.
  • I.-K. Park, Y.J. Kim, T.H. Tran, K.M. Huh, Y.-K. Lee, Water-soluble heparin?PTXconjugates for cancer targeting, Polymer, 51 (2010) 3387-3393.
  • I. Yoshida, K.I. Tashiro, A. Monji, I. Nagata, Y. Hayashi, Y. Mitsuyama, N. Tashiro,Identification of a heparin binding site and the biological activities of the laminin ??1 chaincarboxy?terminal globular domain, Journal of Cellular Physiology, 179 (1999) 18-28.14
  • H.-Y. Lee, Y.-I. Jeong, D.-H. Kim, K.-C. Choi, Permanent hair dye-incorporated13hyaluronic acid nanoparticles, Journal of Microencapsulation, 30 (2013) 189-197.
  • H.-J. Cho, H.Y. Yoon, H. Koo, S.-H. Ko, J.-S. Shim, J.-H. Lee, K. Kim, I. Chan Kwon.and D.-D. Kim, Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE)and Pluronic?? for tumor-targeted delivery of docetaxel, Biomaterials. 32 (2011) 7181-7190.
  • H.-J. Cho, H.Y. Yoon, H. Koo, S.-H. Ko, J.-S. Shim, J.-H. Lee, K. Kim, I. Chan Kwon,D.-D. Kim, Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE)and Pluronic?? for tumor-targeted delivery of docetaxel, Biomaterials, 32 (2011) 7181-7190.
  • H. Maeda, Tumor-selective delivery of macromolecular drugs via the EPR effect:background and future prospects, Bioconjugate Chem. 21 (2010) 797-802.
  • H. Maeda, J. Wu, T. Sawa, Y. Matsumura. and K. Hori, Tumor vascular permeability andthe EPR effect in macromolecular therapeutics: a review, J. Control. Release. 65 (2000) 271-284.
  • H. Maeda, J. Wu, T. Sawa, Y. Matsumura, K. Hori, Tumor vascular permeability and theEPR effect in macromolecular therapeutics: a review, Journal of Controlled Release, 65 (2000)271-284.16
  • H. Buller, M. Gent, A. Gallus, J. Ginsberg, M. Prins, R. Baildon. and J. ten Cate, Lowmolecularweight heparin in the treatment of patients with venous thromboembolism: theColumbus Investigators, The New England Journal of Medicine. 337 (1997) 657-662.
  • G.S. Kwon and T. Okano, Soluble self-assembled block copolymers for drug delivery,Pharm. Res. 16 (1999) 597-600.
  • G.S. Kwon and T. Okano, Polymeric micelles as new drug carriers, Adv. Drug Deliv. Rev.21 (1996) 107-116.
  • G.-B. Jiang, D. Quan, K. Liao, H. Wang, Novel polymer micelles prepared from chitosangrafted hydrophobic palmitoyl groups for drug delivery, Molecular Pharmaceutics, 3 (2006)152-160.
  • G. Saravanakumar, K.H. Min, D.S. Min, A.Y. Kim, C.-M. Lee, Y.W. Cho, S.C. Lee, K.Kim, S.Y. Jeong. and K. Park, Hydrotropic oligomer-conjugated glycol chitosan as a carrierof paclitaxel: Synthesis, characterization, and in vivo biodistribution, J. Control. Release. 140(2009) 210-217.
  • G. Gaucher, M.-H. Dufresne, V.P. Sant, N. Kang, D. Maysinger. and J.-C. Leroux, Blockcopolymer micelles: preparation, characterization and application in drug delivery, J. Control.Release. 109 (2005) 169-188.
  • G. Gaucher, M.-H. Dufresne, V.P. Sant, N. Kang, D. Maysinger, J.-C. Leroux, Blockcopolymer micelles: preparation, characterization and application in drug delivery, Journal ofControlled Release, 109 (2005) 169-188.
  • F.K. Engels, R.A. Mathot. and J. Verweij, Alternative drug formulations of docetaxel: areview, Anti-cancer drugs. 18 (2007) 95-103.
  • F. Esmaeili, R. Dinarvand, M.H. Ghahremani, M. Amini, H. Rouhani, N. Sepehri, S.N.Ostad. and F. Atyabi, Docetaxel?albumin conjugates: preparation, in vitro evaluation andbiodistribution studies, J. Pharm. Sci. 98 (2009) 2718-2730.
  • E. Young, The anti-inflammatory effects of heparin and related compounds, Thromb.Res. 122 (2008) 743-752.
  • E. Persohn, A. Canta, S. Schoepfer, M. Traebert, L. Mueller, A. Gilardini, S. Galbiati, G.47Nicolini, A. Scuteri. and F. Lanzani, Morphological and morphometric analysis of paclitaxeland docetaxel-induced peripheral neuropathy in rats, European journal of cancer. 41 (2005)1460-1466.
  • D. Farge, P. Debourdeau, M. Beckers, C. Baglin, R.M. Bauersachs, B. Brenner, D.Brilhante, A. Falanga, G.T. Gerotzafias, N. Haim, A.K. Kakkar, A.A. Khorana, R. Lecumberri,M. Mandala, M. Marty, M. Monreal, S.A. Mousa, S. Noble, I. Pabinger, P. Prandoni, M.H.Prins, M.H. Qari, M.B. Streiff, K. Syrigos, H. Bounameaux. and H.R. BU Ller, Internationalclinical practice guidelines for the treatment and prophylaxis of venous thromboembolism inpatients with cancer, J. Thromb. Haemost. 11 (2013) 56-70.
  • D. Farge, P. Debourdeau, M. Beckers, C. Baglin, R.M. Bauersachs, B. Brenner, D.Brilhante, A. Falanga, G.T. Gerotzafias, N. Haim, A.K. Kakkar, A.A. Khorana, R. Lecumberri,M. Mandala, M. Marty, M. Monreal, S.A. Mousa, S. Noble, I. Pabinger, P. Prandoni, M.H.Prins, M.H. Qari, M.B. Streiff, K. Syrigos, H. Bounameaux, H.R. BU Ller, Internationalclinical practice guidelines for the treatment and prophylaxis of venous thromboembolism inpatients with cancer, Journal of Thrombosis and Haemostasis, 11 (2013) 56-70.
  • C.F. Mu, P. Balakrishnan, F.D. Cui, Y.M. Yin, Y.B. Lee, H.G. Choi, C.S. Yong, S.J.Chung, C.K. Shim. and D.D. Kim, The effects of mixed MPEG-PLA/Pluronic ?c copolymermicelles on the bioavailability and multidrug resistance of docetaxel, Biomaterials. 31 (2010)2371-2379.
  • C. Pinto Reis, R.J. Neufeld, A.J. Ribeiro, F. Veiga, Nanoencapsulation I. Methods forpreparation of drug-loaded polymeric nanoparticles, Nanomedicine: Nanotechnology,Biology and Medicine, 2 (2006) 8-21.
  • C. He, Y. Hu, L. Yin, C. Tang. and C. Yin, Effects of particle size and surface charge oncellular uptake and biodistribution of polymeric nanoparticles, Biomaterials. 31 (2010) 3657-3666.
  • B. Casu, M. Guerrini, S. Guglieri, A. Naggi, M. Perez, G. Torri, G. Cassinelli, D. Ribatti,P. Carminati. and G. Giannini, Undersulfated and glycol-split heparins endowed withantiangiogenic activity, J. Med. Chem. 47 (2004) 838-848.
  • B. Casu, M. Guerrini, S. Guglieri, A. Naggi, M. Perez, G. Torri, G. Cassinelli, D. Ribatti,P. Carminati, G. Giannini, Undersulfated and glycol-split heparins endowed withantiangiogenic activity, Journal of Medicinal Chemistry, 47 (2004) 838-848.
  • A.Y. Lee, M.N. Levine, R.I. Baker, C. Bowden, A.K. Kakkar, M. Prins, F.R. Rickles, J.A.Julian, S. Haley. and M.J. Kovacs, Low-molecular-weight heparin versus a coumarin for theprevention of recurrent venous thromboembolism in patients with cancer, N. Engl. J. Med.349 (2003) 146-153.
  • A.Y. Lee, M.N. Levine, R.I. Baker, C. Bowden, A.K. Kakkar, M. Prins, F.R. Rickles, J.A.Julian, S. Haley, M.J. Kovacs, Low-molecular-weight heparin versus a coumarin for theprevention of recurrent venous thromboembolism in patients with cancer, New EnglandJournal of Medicine, 349 (2003) 146-153.
  • A.J. Wood, J.I. Weitz, Low-molecular-weight heparins, New England Journal ofMedicine, 337 (1997) 688-699.
  • A. Michael, K. Syrigos. and H. Pandha, Prostate cancer chemotherapy in the era oftargeted therapy, Prostate cancer and prostatic diseases. 12 (2008) 13-16.
  • A. Bhardwaj, V. Balakrishnan, P. Srivastava, H. Sehgal, Self assembled nanoparticle Pb1?xFe xSe/single crystal Si heterojunctions, Current Applied Physics, 10 (2010) 203-207.